|
|
Article: Intercept Researchers Present Data at DDW Highlighting Role of FXR in Inflammatory Bowel Disease.
- Article from:
- PR Newswire
- Article date:
- May 24, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Data Suggests INT-747 May Have Utility as a Potential Treatment for IBD -
LOS ANGELES and NEW YORK, May 24 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases, today reported that researchers affiliated with the company presented data at the Digestive Disease Week annual meeting highlighting the role of the farnesoid X bile acid receptor (FXR) in inflammatory bowel disease. Intercept's lead FXR agonist, INT-747, is in Phase 1 clinical trials to treat liver damage caused by fibrosis and cholestasis in chronic liver ...
Related newspaper, magazine, and journal articles:
|
|
Article: Exelixis, Wyeth Enter $158M Agreement For FXR Program.
BIOWORLD Today;
December 23, 2005 ;
700+ words
... ... compounds that target the farnesoid X receptor (FXR). South San Francisco-based Exelixis ... their ability to modulate the activity of FXR in preclinical studies. The pharmaceutical ... diseases. Wyeth said it plans to move the FXR program into the clinic in the near future ...
|
|